The cytoprotective role of gemcitabine-induced autophagy associated with apoptosis inhibition in triple-negative MDA-MB-231 breast cancer cells
- 6 May 2014
- journal article
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 34 (1) , 276-282
Abstract
Triple-negative breast cancer (TNBC), which is estrogen receptor (ER)-negative, progesterone receptor‑negative and is also negative for HER2 expression, remains a great clinical challenge due to its strong resistance to chemotherapy at the late stage of treatment and relatively unfavorable prognosis. Gemcitabine has been approved by the FDA/SFDA for use as a first-line therapeutic drug against advanced or metastatic breast cancer. Therefore, the clarification of the mechanisms underlying gemcitabine-acquired resistance is of particular importance for the optimal management of TNBC. A number of studies have revealed that autophagy, which has been found to protect cancer cells from anti-cancer drug-induced death, may contribute to the development of drug resistance. However, the association between autophagy and gemcitabine treatment in TNBC cells has yet to be defined. Our study clearly demonstrates that gemcitabine is able to induce mTOR-independent autophagy in human triple‑negative MDA-MB-231 breast cancer cells. In addition, we demonstrate that autophagy protects MDA-MB-231 cells from gemcitabine-induced cell growth inhibition and apoptosis, indicating that gemcitabine can activate autophagy to impair the sensitivity of MDA-MB‑231 cells. Furthermore, as shown by our results, the inhibition of gemcitabine-induced autophagy by chloroquine shifts the expression of the p53 protein, Bcl-2 family proteins and the relative Bax/Bcl-xL ratio in favor of promoting apoptosis. These results reveal that the inhibition of apoptosis may be one of the mechanisms of autophagy-induced cytoprotection in gemcitabine-treated MDA-MB-231 cells. The apoptotic and autophagic processes constitute a mutual inhibition system and jointly seal the fate of TNBC cells that are exposed to gemcitabine. Thus, our study suggests that the combination of an autophagic inhibitor and gemcitabine as a therapeutic strategy may represent a promising approach with greater clinical efficacy for patients with TNBC. However, extended preclinical trials are required to further determine the positive effects of the inhibition of autophagy on the efficacy of gemcitabine.Keywords
This publication has 29 references indexed in Scilit:
- Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- Survival Outcomes for Patients with Metastatic Triple-Negative Breast Cancer: Implications for Clinical Practice and Trial DesignClinical Breast Cancer, 2009
- What is triple-negative breast cancer?European Journal of Cancer, 2008
- Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancerCancer, 2008
- Triple-Negative Breast Cancer: Clinical Features and Patterns of RecurrenceClinical Cancer Research, 2007
- Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotypeCancer, 2007
- Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast CancerJournal of Clinical Oncology, 2006
- A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancerBMC Cancer, 2006
- Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experienceBMC Cancer, 2006
- Phase II Trial of Weekly Docetaxel/Gemcitabine as First-Line Chemotherapy in Patients with Locally Recurrent or Metastatic Breast CancerClinical Breast Cancer, 2006